首页> 美国卫生研究院文献>Microorganisms >Obesity Early Life Gut Microbiota and Antibiotics
【2h】

Obesity Early Life Gut Microbiota and Antibiotics

机译:肥胖早期生命肠道微生物群和抗生素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Obesity is a major public health problem that continues to be one of the leading risk factors for premature death. Early life is a critical period of time when the gut microbiota and host metabolism are developing in tandem and significantly contribute to long-term health outcomes. Dysbiosis of the gut microbiota, particularly in early life, can have detrimental effects on host health and increase the susceptibility of developing obesity later in life. Antibiotics are an essential lifesaving treatment; however, their use in early life may not be without risk. Antibiotics are a leading cause of intestinal dysbiosis, and early life administration is associated with obesity risk. The following review explores the relevant literature that simultaneously examines antibiotic-induced dysbiosis and obesity risk. Current evidence suggests that disruptions to the composition and maturation of the gut microbiota caused by antibiotic use in early life are a key mechanism linking the association between antibiotics and obesity. Without compromising clinical practice, increased consideration of the long-term adverse effects of antibiotic treatment on host health, particularly when used in early life is warranted. Novel adjunct interventions should be investigated (e.g., prebiotics) to help mitigate metabolic risk when antibiotic treatment is clinically necessary.
机译:肥胖是一个主要的公共卫生问题,继续成为过早死亡的主要风险因素之一。早期生命是肠道微生物群和宿主代谢在串联发展并显着促进长期健康结果的关键时期。肠道微生物群的脱瘤,特别是在早期生命中,对宿主健康产生有害影响,并提高人生后期发展肥胖的敏感性。抗生素是必不可少的救生治疗;然而,他们在早期生活中的使用可能没有风险。抗生素是肠道失恋的主要原因,早期生命给药与肥胖风险有关。以下综述探讨了同时检查抗生素诱导的嗜血症和肥胖风险的相关文献。目前的证据表明,通过早期抗生素使用引起的肠道微生物的组成和成熟的破坏是将抗生素和肥胖症之间联系的关键机制。在不影响临床实践的情况下,增加了对抗生素治疗对宿主健康的长期不良影响的思考,特别是在初期使用时受到了较早的。应研究新型辅助干预(例如,益生元),以帮助减轻抗生素治疗时的代谢风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号